---
figid: PMC7280434__fonc-10-00764-g0001
figtitle: Current strategies to overcome multidrug resistance
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Cinchona pubescens
organisms_ner:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC7280434
filename: fonc-10-00764-g0001.jpg
figlink: pmc/articles/PMC7280434/figure/F1/
number: F1
caption: 'Current strategies to overcome multidrug resistance. In addition to the
  well-known ABC transporters, many drug resistance mechanisms of CSCs have been identified,
  including ALDHs, EMT, epigenetic changes, tumor microenvironment, and stemness-related
  signaling pathways. The drugs that inhibit each pathway are described: (i) ABC transporter
  inhibitors and non-substrates; (ii) ALDH inhibitors; (iii) AMPK activators; (iv)
  BET inhibitors, HDAC inhibitors, and KDM1 inhibitors; (v) VEGF inhibitors, RTK inhibitors,
  and vascular disrupting agents; (VI) Notch inhibitors, Smo inhibitors, and Wnt/β-catenin
  inhibitors. ABC, ATP binding cassette; ALDHs, aldehyde dehydrogenases; AMPK, AMP-activated
  kinase; BET, bromodomain and extra-terminal; CSCs, cancer stem cells; EMT, epithelial
  to mesenchymal transition; HDAC, histone deacetylase; KDM1, lysine-specific demethylase
  1; MDR, multidrug resistance; RTK, receptor tyrosine kinase; VEGF, vascular endothelial
  growth factor.'
papertitle: Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance.
reftext: Yena Cho, et al. Front Oncol. 2020;10:764.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.7313578
figid_alias: PMC7280434__F1
figtype: Figure
redirect_from: /figures/PMC7280434__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7280434__fonc-10-00764-g0001.html
  '@type': Dataset
  description: 'Current strategies to overcome multidrug resistance. In addition to
    the well-known ABC transporters, many drug resistance mechanisms of CSCs have
    been identified, including ALDHs, EMT, epigenetic changes, tumor microenvironment,
    and stemness-related signaling pathways. The drugs that inhibit each pathway are
    described: (i) ABC transporter inhibitors and non-substrates; (ii) ALDH inhibitors;
    (iii) AMPK activators; (iv) BET inhibitors, HDAC inhibitors, and KDM1 inhibitors;
    (v) VEGF inhibitors, RTK inhibitors, and vascular disrupting agents; (VI) Notch
    inhibitors, Smo inhibitors, and Wnt/β-catenin inhibitors. ABC, ATP binding cassette;
    ALDHs, aldehyde dehydrogenases; AMPK, AMP-activated kinase; BET, bromodomain and
    extra-terminal; CSCs, cancer stem cells; EMT, epithelial to mesenchymal transition;
    HDAC, histone deacetylase; KDM1, lysine-specific demethylase 1; MDR, multidrug
    resistance; RTK, receptor tyrosine kinase; VEGF, vascular endothelial growth factor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Abcb1b
  - Mod2
  - Itk
  - Slc22a3
  - Vegfa
  - Abcb1a
  - Abcc1
  - Prl2c2
  - Ccl6
  - Cdh1
  - Fzr1
  - Ptprj
  - Dner
  - ac
  - Gabrg2
  - Gli1
  - Smo
  - Smox
  - Ctnnb1
  - Aldh1a1
  - Kdm1a
  - Ptch1
  - Aldh3a1
  - Abcg2
  - Shh
  - Prkaa2
  - Pgp
  - Wnt2
  - Notch1
  - ITK
  - SLC22A3
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - ABCB6
  - ABCB1
  - CD9
  - MDM4
  - ABCC1
  - MSH3
  - CDH1
  - FZR1
  - IGBP1
  - CCNK
  - CDK9
  - CCNT1
  - CCNT2
  - HEXIM1
  - HEXIM2
  - DNER
  - ADCY1
  - ADCY2
  - ADCY3
  - ADCY4
  - ADCY5
  - ADCY6
  - ADCY7
  - ADCY8
  - ADCY9
  - ADCY10
  - GLI1
  - TMPRSS11D
  - SMO
  - SMOX
  - CTNNB1
  - HDAC9
  - HDAC1
  - HDAC2
  - HDAC3
  - HDAC8
  - HDAC4
  - HDAC5
  - HDAC7
  - HDAC6
  - HDAC10
  - SIRT1
  - SIRT2
  - SIRT3
  - SIRT4
  - SIRT5
  - SIRT6
  - SIRT7
  - HDAC11
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - ALDH1A1
  - KDM1A
  - PTCH1
  - CASP1
  - CASP2
  - CASP4
  - CASP5
  - CASP6
  - CASP8
  - CASP9
  - CASP10
  - CASP12
  - CASP14
  - CASP3
  - CASP7
  - NOTCH1
  - NOTCH2
  - NOTCH3
  - NOTCH4
  - ALDH1A2
  - ALDH1A3
  - ALDH2
  - ALDH3A1
  - ALDH3A2
  - ALDH3B1
  - ALDH5A1
  - ALDH7A1
  - ALDH9A1
  - ABCG2
  - SHH
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - SNF4Agamma
  - AMPKalpha
  - SRPK
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
  - Tie
  - Ras85D
  - InR
  - Mdr65
  - MRP
  - shg
  - Prosalpha4
  - alphaTub67C
  - nAChRalpha4
  - Cdk9
  - CycT
  - bet
  - Gli
  - ci
  - hat
  - Elp3
  - CG1894
  - chm
  - smo
  - sm
  - .na.character
  - arm
  - Me
  - Wnt5
  - Wnt4
  - wg
  - ptc
  - Cyt-c-d
  - Cyt-c-p
  - Aldh
  - Aldh-III
  - Metformin
  - Thalidezine
  - Sorafenib
  - Ixabepilone
  - Cabazitaxel
  - Vinflunine
  - Combretastatin
  - Ac
  - 'Me  Me '
  - Cyclopamine
  - KDMS Me  Vorinostat
  - PTCH
  - RO4929097
  - Disulfiram
  - Tretinoin
  - Cancer
  - Hypoxia
---
